The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial
Abstract
OBJECTIVE: Current drug therapies for generalized anxiety disorder have limitations. In a controlled trial, the novel agent pregabalin was studied for the treatment of patients with generalized anxiety disorder. METHOD: In this double-blind study, patients with DSM-IV generalized anxiety disorder were randomly assigned to receive pregabalin (150 mg/day or 600 mg/day), lorazepam (6 mg/day), or placebo. A 1-week placebo lead-in was followed by 4 weeks of treatment and then a 1-week dose taper. The primary efficacy measure was the Hamilton Anxiety Rating Scale score at endpoint. RESULTS: A total of 276 patients were randomly assigned to a treatment group and received at least one dose of their assigned medication. Fewer patients given lorazepam (59%, N=40 of 68) completed the trial than did those given placebo (73%, N=50 of 69), 600 mg/day of pregabalin (71%, N=50 of 70), or 150 mg/day or pregabalin (90%, N=62 of 69). The mean baseline-to-endpoint decreases in total Hamilton anxiety scale score in the patients given 150 mg/day of pregabalin (-9.2), 600 mg/day of pregabalin (-10.3), and lorazepam (-12.0) were significantly greater than the decrease in those given placebo (-6.8). As early as the week 1 observation, pregabalin significantly reduced the total Hamilton anxiety scale score compared with placebo. The most frequent adverse events reported for pregabalin and lorazepam were somnolence and dizziness. There were no serious adverse events reported by patients given pregabalin, and no withdrawal syndrome was associated with pregabalin treatment. CONCLUSIONS: These results indicate that pregabalin is an effective, rapidly acting, and safe treatment for generalized anxiety disorder. In short-term treatment, pregabalin does not appear to have the withdrawal symptoms associated with the benzodiazepines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Applied Linear Statistical Models
Ziegel, E. R., Neter, J., Wasserman, W., & Kutner, M. (1992) · Technometrics · doi:10.2307/1269588 · Cited by 9,907
Applied Linear Statistical Models
(1997) · Technometrics · doi:10.1080/00401706.1997.10485141 · Cited by 7,185
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Sheehan, D., Lecrubier, Y., Harnett Sheehan, K., Janavs, J., Weiller, E., Keskiner, A., Schinka, J., Knapp, E., Sheehan, M., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83297-x · Cited by 2,149
The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium Channel
Gee, N. S., Brown, J. P., Dissanayake, V. U. K., Offord, J., Thurlow, R., & Woodruff, G. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5768 · Cited by 1,181
Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex
Fink, K., Dooley, D. J., Meder, W. P., Suman-Chauhan, N., Duffy, S., Clusmann, H., & Göthert, M. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(01)00172-1 · Cited by 496
Kessler, R. C., DuPont, R. L., Berglund, P., & Wittchen, H.-U. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1915 · Cited by 486
RASKIN, A., SCHULTERBRANDT, J., REATIG, N., & McKEON, J. J. (1969) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196901000-00010 · Cited by 373
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin
Dooley, D. J., Mieske, C. A., & Borosky, S. A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00769-2 · Cited by 226
Dooley, D. J., Donovan, C. M., & Pugsley, T. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39009-3 · Cited by 217
Maneuf, Y. P., Hughes, J., & McKnight, A. T. (2001) · Pain · doi:10.1016/s0304-3959(01)00316-5 · Cited by 184
Clinical Effects of Buspirone in Social Phobia: A Double-Blind Placebo-Controlled Study
van Vliet, I. M., den Boer, J. A., Westenberg, H. G. M., & Pian, K. L. H. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0405 · Cited by 124
A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder
Kramer, M. S., Cutler, N. R., Ballenger, J. C., Patterson, W. M., Mendels, J., Chenault, A., Shrivastava, R. K., Matzura‐Wolfe, D., Lines, C., & Reines, S. A. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00190-e · Cited by 117
Sheehan, D. V., Raj, A. B., Harnett-Sheehan, K., Soto, S., & Knapp, E. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03405.x · Cited by 86
Lecrubier, Y., Puech, A. J., Azcona, A., Bailey, P., & Lataste, X. (1993) · Psychopharmacology · doi:10.1007/bf02247373 · Cited by 83
Adams, J. B., Pyke, R. E., Costa, J., Cutler, N. R., Schweizer, E. E., Wilcox, C. S., Wisselink, P., Greiner, M., Pierce, M., & Pande, A. C. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199512000-00007 · Cited by 79
Self-citationOutpatient treatment of neurotic depression: medication and group psychotherapy.
Lipman, R. S., & Covi, L. (1976) · PubMed · Cited by 74
Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder
Pande, A. C., Greiner, M., Adams, J. B., Lydiard, R. B., & Pierce, M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00090-6 · Cited by 54
Self-citationEfficacy of ondansetron in the treatment of generalized anxiety disorder
Freeman, A. M., Westphal, J. R., Norris, G., Roggero, B. A., Webb, P. B., Freeman, K., Rush, J., Hearne, E. M., & Evoniuk, G. E. (1997) · Depression and Anxiety · Cited by 30
Cited by
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Crofford, L. J., Rowbotham, M. C., Mease, P. J., Russell, I. J., Dworkin, R. H., Corbin, A. E., Young, J. P., LaMoreaux, L. K., Martin, S. A., Sharma, U., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20983 · Cited by 654
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Richter, R. W., Portenoy, R., Sharma, U., Lamoreaux, L., Bockbrader, H., & Knapp, L. E. (2005) · The Journal of Pain · doi:10.1016/j.jpain.2004.12.007 · Cited by 473
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Metadata
- Authors
- Pande, A. C., Crockatt, J. G., Feltner, D. E., Janney, C. A., Smith, W. T., Weisler, R., Londborg, P. D., Bielski, R. J., Zimbroff, D. L., Davidson, J. R. T., & Liu-Dumaw, M.
- Venue
- American Journal of Psychiatry
- Published
- 2003-03
- Volume
- 160
- Issue
- 3
- Pages
- 533-540
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2132270420
- Cited by
- 314
- References
- 22
- FWCI
- 35.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.